Wells Fargo & Company Red Hill Biopharma Ltd. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.14 - $695.9 $0 - $695	-1 Reduced 0.05%	1,942 $0
Q2 2022 Aug 12, 2022	BUY	$0.63 - $2.58 $630 - $2,580	1,000 Added 106.04%	1,943 $2,000
Q1 2022 May 16, 2022	SELL	$1.65 - $3.12 $2,793 - $5,282	-1,693 Reduced 64.23%	943 $2,000
Q4 2021 Feb 14, 2022	SELL	$2.31 - $5.85 $649,622 - $1.65 Million	-281,222 Reduced 99.07%	2,636 $7,000
Q3 2021 Nov 15, 2021	BUY	$4.55 - $10.36 $117,572 - $267,702	25,840 Added 10.01%	283,858 $1.3 Million
Q2 2021 Aug 16, 2021	BUY	$5.98 - $7.51 $345,153 - $433,462	57,718 Added 28.82%	258,018 $1.78 Million
Q1 2021 May 13, 2021	BUY	$6.98 - $11.29 $455,863 - $737,349	65,310 Added 48.38%	200,300 $1.47 Million
Q4 2020 Feb 09, 2021	SELL	$7.81 - $10.39 $17,963 - $23,897	-2,300 Reduced 1.68%	134,990 $1.09 Million
Q3 2020 Nov 05, 2020	BUY	$6.34 - $10.83 $861,701 - $1.47 Million	135,915 Added 9884.73%	137,290 $1.4 Million
Q2 2020 Aug 13, 2020	BUY	$4.6 - $8.6 $2,645 - $4,945	575 Added 71.88%	1,375 $9,000
Q1 2020 May 14, 2020	BUY	$3.51 - $6.17 $2,808 - $4,936	800 New	800 $4,000

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $465M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.